imipenem, anhydrous has been researched along with Infections, Coronavirus in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Chen, DG; Kong, DP; Su, L; Tu, Y; Wang, ZB; Zhang, CX; Zhang, WN; Zhuang, CL | 1 |
Al-Tawfiq, JA; Dib, J; Memish, ZA; Momattin, H | 1 |
2 other study(ies) available for imipenem, anhydrous and Infections, Coronavirus
Article | Year |
---|---|
Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.
Topics: Acute Lung Injury; Animals; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Repositioning; Guanine; Humans; Imipenem; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Pandemics; Pneumonia, Viral; Tumor Necrosis Factor-alpha | 2020 |
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Coronavirus; Coronavirus Infections; Critical Illness; Diabetes Mellitus; Female; Humans; Hypertension; Imipenem; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Renal Insufficiency, Chronic; Respiration, Artificial; Respiratory Tract Infections; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2014 |